Connective Tissue Lesions

8/19/2019 Connective Tissue Lesions

1/285

CONNECTIVE TISSUE LESIONS


2/285

CONNECTIVE TISSUE LESIONS

FIBROUS

TISSUENEURAL TISSUE MUSCLE TISSUE

ADIPOSE

TISSUE

VASCULAR

TISSUE

OSSEOUS &

CARTILAGINOUSTISSUES


3/285

FIBROUS TISSUE

FIBROMA

Also known as:

Irritation fibroma

Focal fibrous !"#r"lasia

Fibrous no$ul#

Traumatic fibroma


4/285

FIBROMA

%!"#r"lasia of fibrous conn#cti tissu#

tat #&ols in r#s"ons# to cronic

irritation in wic t#r# is #'t#nsi

#laboration of colla(#n r#s#mblin( scar

tissu#.


5/285

FIBROMA

Most common tumor of the or! c"#t$

Not true neo%!sm of f#ro!sts

Re%resents h$%er%!s# of f#rous t#ssue #nres%onse to trum or #rr#tt#on

Pro'uct#on of mture co!!(en un'!es #s#ncrese'


6/285

FIBROMA

chee) #t#n(

L#% #t#n(

Denture #rr#tt#on

Most common

contributin( factors


7/285

FIBROMA

Most common s#te* ucc! mucos !on(

the #te !#ne.


8/285

FIBROMA

Other common s#tes:

L#! mucos

Ton(ue

(#n(#"


9/285

FIBROMA

A%%ernce:

Smooth surfce'

P#n) 'ome sh%e' no'u!e resem!#n( the

surroun'#n( mucos.

Cn e +h#te 'ue to h$%er)ertos#s.


10/285

FIBROMA

Sess#!e or %e'uncu!te'.

Most!$ sess#!e.

S#,e* -./cm or !ess #n '#meter .

A(e* 012th 'ec'e

Se3* more #n Fem!es


11/285

FIBROMA

Cn re%resent f#rous mturt#on of %re1

e3#st#n( P$o(en#c (rnu!om.


12/285

FIBROMA

Fren! T(:

T$%e of f#rom tht #s foun' on the

m3#!!r$ !#! frenum.

Sm!! #n s#,e

As$m%tomt#c

E3o%h$t#c (ro+th


13/285

HISTOPATHOLOGY OF FIBROMA


14/285


15/285


16/285


17/285

TREATMENT

Sur(#c! e3c#s#on

Recurrence #s rre.

Im%ortnt to sen' for #o%s$.

No tretment re4u#re' for Fren! t(


18/285

GIANT CELL FIBROMA

A f#rous tumor +h#ch 'oes not %%er to

e ssoc#te' +#th chron#c #rr#tt#on.


19/285

GIANT CELL FIBROMA


20/285

GIANT CELL FIBROMA


21/285

HISTOPATHOLOGICAL

FEATURES

E%#the!#um #s th#n & tro%h#c +#th nrro+ &

e!on(te' rete r#'(es.

Mss of !oose!$ rrn(e' "scu!r

f#rous connect#"e t#ssue.

Presence of !r(e5ste!!te mu!t#nuc!ete'

f#ro!sts +#th#n su%erf#c#! connect#"e

t#ssue


22/285


23/285


24/285


25/285


26/285

TREATMENT

Sur(#c! e3c#s#on.


27/285

INFLAMMATORY FIBROUS

HYPERPLASIA

A!so )no+n s:

E%u!#s F#ssurtum

Denture E%u!#s

Denture #n6ur$ tumor


28/285

INFLAMMATORY FIBROUS

HYPERPLASIA

Tumor !#)e h$%er%!s# of f#rous

connect#"e t#ssue tht 'e"e!o%s #n

ssoc#t#on +#th the f!n(e of n #!!1f#tt#n(

com%!ete or %rt#! 'enture.


29/285


30/285

CLINICAL FEATURES


31/285

CLINICAL FEATURES


32/285

CLINICAL FEATURES


33/285

CLINICAL FEATURES


34/285

HISTOPATHOLOGICAL

FEATURES


35/285

HISTOPATHOLOGICAL

FEATURES


36/285

INFLAMMATORY PAPILLARY

HYPERPLASIA

Mu!t#%!e sm!! no'u!es tht cons#st of

%ro!#fert#on of f#rous connect#"e t#ssue

+#th n ssoc#te' chron#c #nf!mmt#onfoun' un'er #!!1f#tt#n( 'entures.


37/285


38/285


HYPERPLASIA


39/285


HYPERPLASIA


40/285

HISTOPATHOLOGY

Gross s%ec#men hs %o!$%o#'!

%%ernce.

Mu!t#%!e sm!! roun' no'u!es re seen

co"ere' +#th strt#f#e' s4umouse%#the!#um.

E%#the!#um sho+s %seu'oe%#the!#omtous

h$%er%!s#.Dense connect#"e t#ssue.

Scttere' #nf!mmtor$ ce!!s.


41/285


42/285

TREATMENT

78PERPLASTIC TISSUE S7OULD BE

REMOVED BEFORE FABRICATION OF

A NE9 DENTURE.


43/285

HEREDITARY GINGIVAL

FIBROMATOSIS

7ere'#tr$ form of (ener!#,e' (#n(#"!

h$%er%!s# #n +h#ch the utosom!

'om#nnt form m$e ssoc#te' +#thh$%ertr#chos#s5 crn#ofc#!

'eform#t#es5e%#!e%s$ n' ment!

retr't#on.


44/285

HEREDITARY GINGIVAL

FIBROMATOSIS


45/285

CLINICAL FEATURES


46/285

AUTOSOMAL


47/285

AUTOSOMAL

DOMINANT TYPE


48/285

RECESSIVE FORM


49/285

HISTOPATHOLOGY


50/285

PERIPHERAL OSSIFYING

FIBROMA

G#n(#"! no'u!e cons#st#n( of rect#"e

h$%er%!s# of connect#"e t#ssue

cont#n#n( foc! res of one.

A!so )no+n s:

Oss#f$#n( F#ro#' E%u!#s

Per#%her! F#rom +#th C!c#f#ct#on

C!c#f$#n( F#ro!st#c Grnu!om


51/285


FIBROMA


52/285


FIBROMA

OSS G


53/285


FIBROMA

S#te* Occurs e3c!us#"e!$ on the (#n(#"



54/285


FIBROMA

A%%ernce* no'u!r mss

Pe'uncu!te':sess#!e



55/285


FIBROMA

A%%ernce* co!or rn(es from %#n) to

re'.

Most!$ u!certe'

In#t#!!$ u!certe'5 o!'er !es#ons'emonstrte he!#n( of u!cer & n #ntct

surfce.



56/285


FIBROMA



57/285


FIBROMA


58/285

HISTOPATHOLOGY


59/285


60/285

HISTOPATHOLOGY


61/285


62/285


63/285


64/285

PYOGENIC


65/285

PYOGENIC

GRANULOMA

Common tumor !#)e (ro+th of the or!

c"#t$.

Non1neo%!st#c.

A!so )no+n s ;Lou!!r C%#!!r$


66/285

PYOGENIC

GRANULOMA

Current!$ cte(or#,e' s vascular tumor

un'er the c!ss#f#ct#on scheme of the

Internt#on! soc#et$ for the stu'$ ofVscu!r Anom!#es

PYOGENIC


67/285

PYOGENIC

GRANULOMA

Fst (ro+#n( rect#"e %ro!#fert#on of

en'othe!#! ce!!s common!$ on the

(#n(#" & usu!!$ #n res%onse to chron#c#rr#tt#on.

A foc! rect#"e (ro+th of f#ro"scu!r or

(rnu!t#on t#ssue +#th e3tens#"een'othe!#! %ro!#fert#on.

PYOGENIC


68/285

PYOGENIC

GRANULOMA

PRECIPITATING


69/285

PRECIPITATING

FACTORS

PYOGENIC


70/285

PYOGENIC

GRANULOMA

PYOGENIC


71/285

PYOGENIC

GRANULOMA


72/285

PYOGENIC


73/285

PYOGENIC

GRANULOMA

PYOGENIC


74/285

PYOGENIC

GRANULOMA


75/285

PREGNANCY TUMOR


76/285

PREGNANCY TUMOR

DIFFERENTIAL


77/285

DIFFERENTIAL

DIAGNOSIS

S O O OG


78/285

HISTOPATHOLOGY

A h#(h!$ "scu!r %ro!#fert#on resem!#n((rnu!t#on t#ssue.

Numerous sm!! & !r(e en'othe!#! !#ne'

chnne!s en(or(e' +#th RBCs.Vesse!s re rrn(e' #n !ou!r %ttern

tht=s +h$ (#"en the nme !ou!r

c%#!!r$ hemn(#om.

Surfce #s u!certe'5 co"ere' $

f#r#no%uru!ent memrne.

HISTOPATHOLOGY


79/285

HISTOPATHOLOGY

A m#3e' #nf!mmtor$ #nf#!trte #s seencom%r#s#n( of neutro%h#!s5%!sm ce!!s &

!$m%hoc$tes.

Neutro%h#!s re more to+r's theu!certe' surfce.

Chron#c #nf!mmtor$ ce!!s re 'ee%er .

O!'er !es#ons h"e more f#rouscom%onent.


80/285


81/285


82/285

TREATMENT


83/285

TREATMENT

BENIGN FIBROUS


84/285

BENIGN FIBROUS

HISTIOCYTOMA

A true neo%!sm h"#n( f#ro!st#c &

h#st#oc$t#c '#fferent#t#on.

A!so )no+n s:Dermtof#rom

Sc!eros#n( hemn(#om

F#ro3nthomNo'u!r sue%#'erm! f#ros#s.

BENIGN FIBROUS


85/285

BENIGN FIBROUS

HISTIOCYTOMA

CUTANEOUS LESIONS


86/285

CUTANEOUS LESIONS

ORAL LESIONS


87/285

ORAL LESIONS

HISTOPATHOLOGY


88/285

HISTOPATHOLOGY

HISTOPATHOLOGY


89/285

HISTOPATHOLOGY

Pro!#fert#on of s%#n'!e sh%e' f#ro!sts +#th"es#cu!r nuc!e#.

Arrn(e' #n short #ntersect#n( fsc#c!es ;stor#form

%ttern< ecuse #t resem!es str+ mt.

Roun'e' h#st#oc$tes

L#%#' cont#n#n( 3nthom ce!!s

Mut!#nuc!ete' (#nt ce!!s

L$m%hoc$tesM$3o#' chn(e or h$!#n#,t#on cn e seen

foc!!$.


90/285


91/285


92/285

TREATMENT


93/285

TREATMENT

Sur(#c! e3c#s#on

MALIGNANT FIBROUS


94/285

HISTIOCYTOMA

M!#(nnt neo%!sm of f#ro!sts +#th

%ro%ens#t$ to '#fferent#te #nto h#st#oc$t#c

& f#roh#stoc$t#c ce!!s.

MALIGNANT FIBROUS


95/285

HISTIOCYTOMA

MALIGNANT FIBROUS


96/285

HISTIOCYTOMA

MALIGNANT FIBROUS


97/285

HISTIOCYTOMA

HISTOLOGICAL


98/285

SUBTYPES

STORIFORM-PLEOMORPHIC


99/285

TYPE

Short fsc#c!es of %!um% s%#n'!e sh%e'ce!!s rrn(e' #n stor#form %tten.

%!eomor%h#c & (#nt ce!!s re seen +#th

un'nt c$to%!smFom$ ce!!s re !so seen

Nuc!e# sho+ mr)e' %!eomor%h#sm5 h#(h

m#tot#c ct#"#t$ & t$%#c! m#tot#c f#(ures.In"s#on #nto '6cent structures seen.

STORIFORM


100/285

STORIFORM

GIANT CELL


101/285

GIANT CELL

PLEOMORPHIC


102/285

PLEOMORPHIC

TREATMENT


103/285

TREATMENT

A((ress#"e tumor

R'#c! sur(#c! e3c#s#on

40%recurrence rte

40%metsts#s seen

Or! tumors h"e +orst %ro(nos#s.

FIBROSARCOMA


104/285

FIBROSARCOMA

M!#(nnt neo%!sm of f#ro!st#c ce!!s.

FIBROSARCOMA


105/285

FIBROSARCOMA

Or!c"#t$

G#n(#"

F!oor ofthe mouth

Bucc!mucos

Ton(ue

Mn'#!e

Most common

#n e3tremet#es.

On!$ ->? #n

he' & nec)

FIBROSARCOMA


106/285

FIBROSARCOMA

•Ch#!'ren &$oun( 'u!ts A(e

•No (en'er

%re'#!ect#onGen'er

FIBROSARCOMA


107/285

FIBROSARCOMA

C!#n#c! Fetures

R%#'!$%ro!#fert#n(

tumor

F#rm &#n'urte'

on%!%t#on

U!cert#on

No c%su!e

F#3t#on to'6centstructures

FIBROSARCOMA


108/285

FIBROSARCOMA

R'#o(r%h#c Fetures

Shr%!$'ef#ne'

r'#o!ucenc#es

Rootresor%t#on

Tooth'#s%!cement

Cort#c!

e3%ns#on

HISTOPATHOLOGY


109/285

HISTOPATHOLOGY

7#(h!$ ce!!u!r tumor

Com%ose' of ce!!s h"#n( n%!st#c

s%#n'!e sh%e' nuc!e#.

At$%#c! m#tot#c f#(ures re numerousCe!!s re rrn(e' #n fsc#c!es )no+ s

@herr#n(one %ttern’


110/285


111/285


112/285

TREATMENT


113/285

TREATMENT

A((ress#"e tumor

9#'e sur(#c! e3c#s#on

50%recurrence rtePro(nos#s #s not (oo'.

FIBROMATOSIS


114/285

FIBROMATOSIS

Ben#(n '#ffuse #nf#!trt#"e %ro!#fert#on of

f#ro!sts & mture co!!(en occurr#n(

+#th#n the soft t#ssues of he' & nec) #n$oun( %t#ents.

FIBROMATOSIS


115/285

FIBROMATOSIS

FIBROMATOSIS


116/285

FIBROMATOSIS

Gen'erNo

%re'#!ect#on

FIBROMATOSIS OF


117/285

NECK

ORAL FIBROMATOSIS


118/285

ORAL FIBROMATOSIS


119/285


120/285


121/285

DESMOPLASTIC FIBROMA


122/285


Ben#(n '#ffuse #nf#!trt#"e %ro!#fert#on of

f#ro!sts & mture co!!(en occurr#n(

%r#mr#!$ +#th#n the mn'#!e #n $oun(%t#ents.



123/285


S#te* D#st#nct ((ress#"e tumor occurr#n(

+#th#n the mn'#!e.



124/285

S O S C O

8oun( %t#ents Bon$ e3%ns#on

D#s%!cement of teeth Resor%t#on of roots

Un#!ocu!r:mu!t#!ocu!rr'#o!ucenc$

9e!! 'ef#ne' mr(#nst the r'#o(r%h



125/285


126/285

NEURAL TISSUE


127/285

NEURAL TISSUE

Trumt#c Neurom Neurof#rom

Neru#!emom Neurof#romtos#s

Neur!t#ssue

TRAUMATIC NEUROMA


128/285

U C U O

P#nfu! no'u!r %ro!#fert#on of ner"e &f#rous t#ssue of the ner"e sheth

resu!t#n( from the fut#!e ttem%t of ner"e

f#ers to reun#te +#th the#r se"ere' '#st!%ort#on.


129/285

TRAUMATIC NEUROMA OF

ORAL MUCOSA


130/285

ORAL MUCOSA


131/285


132/285


133/285

HISTOPATHOLOGY


134/285

7%h,r' %ro!#fert#on of mture m$e!#nte'

& unm$e!#nte' ner"e un'!es.

F#rous connect#"e t#ssue strom rn(es

from 'ense!$ co!!(en#,e' to m$3omtous

#n nture.

M#!' chron#c #nf!mmtor$ #nf#!trte.


135/285


136/285


137/285

TREATMENT


138/285

Sur(#c! e3c#s#on #nc!u'#n( sm!! %ort#on

of #n"o!"e' ner"e un'!e.

Do no recur ut %#n %ers#sts or return

!ter .

NEURILEMOMA(SCHWANNOM

A)


139/285

A)

9e!! 'emrcte' en#(n !es#on cons#st#n(

of f#ro!st#c %ro!#fert#on of the ner"e

sheth ce!! sch+nn ce!! %ro'uc#n('#st#nct#"e %tterns reffere' to s Anton#

A n' Anton# B t#ssue.


A)


140/285

A)

Ben#(n neur! neo%!sm of sch+nn ce!!or#(#n.

Uncommon tumor .

25-48%occur #n he' & nec).


A)


141/285

A)


A)


142/285

A)

HISTOPATHOLOGY


143/285

An enc%su!te' tumor .Sho+s t+o m#crosco%#c %tterns:

ANTONI A


144/285

Strem#n( fsc#c!es of s%#n'!e sh%e'sch+nn ce!!s.

These ce!!s form %!#s'e' rrn(ement

roun' centr! eos#no%h#!#c ce!!u!r,one )no+n s ;"eroc$ o'#es”

Veroc$ o'#es re re'u%!#cte' sement

memrne & c$to%!sm#c %rocesses


145/285


146/285

ANTONI B


147/285

Less ce!!u!r Less or(n#,e'

S%#n'!e ce!!s re rn'om!$ rrn(e'

+#th#n !oose m$3omtous strom


148/285


149/285

DEGENERATIVE

CHANGES


150/285

CHANGES

7emorrh(e

7emos#'er#n 'e%os#ts

Inf!mmt#on

F#ros#s

Nuc!er t$%#

GRANULAR CELL

TUMOR


151/285

TUMOR

Sumucos! mss cons#st#n( of '#ffusesheets of !r(e ce!!s of e#ther ner"e or

musc!e or#(#n +#th c$to%!sm of

'ense!$ %c)e' eos#no%h#!#c (rnu!es

!$sosom! o'#es n' common!$ foun'

on the 'ors! surfce of ton(ue.

GRANULAR CELL

TUMOR


152/285

TUMOR

GRANULAR CELL

TUMOR


153/285

TUMOR

APPEARANCE


154/285

GRANULAR CELL

TUMOR


155/285

TUMOR

Com%ose' of !r(e %o!$(on! ce!!s7"#n( un'nt %!e eos#no%h#!#c

c$to%!sm & "es#cu!r nuc!e#

GRANULAR CELL

TUMOR


156/285

TUMOR

Ce!!s re rrn(e' #n sheets5 cor's ornests.

Ce!! or'ers re #n'#st#nct.

GRANULAR CELL

TUMOR


157/285

TUMOR

GRANULAR CELL

TUMOR


158/285

TUMOR

S#(n#f#cnt m#crosco%#c f#n'#n( #s%seu'oe%#the!#omtous h$%er%!s# of

o"er!$#n( e%#the!#um.

Cn e m#st)en for SCC

IMMUNOMARKERS


159/285

S1->>NSE neuron s%ec#f#c eno!se

Lm#n#n

TREATMENT


160/285

Conser"t#"e !oc! e3c#s#on.

CONEGNITAL EPULIS


161/285

Pe'uncu!te' (ro+th on the nter#or

m3#!! or mn'#!e of ne+orns tht #s

com%ose' of (rnu!r ce!!s.

A!so )no+n s:

Con(en#t! (#n(#"! (rnu!r ce!! tumor

Con(en#t! (rnu!r ce!! e%u!#sCon(en#t! e%u!#s of the ne+orn

CONEGNITAL EPULIS


162/285

Uncommon soft t#ssue tumor tht occurs!most e3c!us#"e!$ on the !"eo!r r#'(es

of ne+orn.

A!so seen on the ton(ue.


163/285

CLINICAL FEATURES


164/285

HISTOPATHOLOGY


165/285

Lr(e roun'e' ce!!s +#th un'nt(rnu!r eos#no%h#!#c c$to%!sm

Roun' to o"! so%h#!#c nuc!e#.

Atro%h$ of rete r#'(es seen #n o"er!$#n(e%#the!#um.

Tumor ce!!s re ne(t#"e for S1->>


166/285

TREATMENT


167/285

Sur(#c! e3c#s#on. After #rth tumor sto%s (ro+#n( & 'ecrese

#n s#,e.

LIPOMA


168/285


169/285


170/285

ORAL LIPOMA


171/285

ORAL LIPOMA


172/285


173/285

HISTOPATHOLOGY


174/285

9e!! c#rcumscr#e' tumor +#th th#n

f#rous c%su!e.

Com%ose' of mture ft ce!!s +h#chc!ose!$ resem!e norm! ft ce!!s.

Lou!r rrn(ement of ce!!s #s seen.


175/285


176/285


177/285

VARIANTS


178/285

TREATMENT


179/285

Conser"t#"e !oc! e3c#s#on.

Vr#nts 'o not ffect the %ro(nos#s.

Inf#!trt#"e !#%oms h"e h#(h recurrence

rte.

LIPOSARCOMA


180/285


181/285

LIPOSARCOMA


182/285

LIPOSARCOMA


183/285

WELL-DIFFERENTIATED

LIPOSARCOMA


184/285

Most common #n the or! c"#t$.55-90%of !! cses.

Resem!e en#(n !#%oms

Sho+ scttere' !#%o!sts & t$%#c!h$%erchromt#c strom! ce!!s.


185/285


186/285

MYXOID

LIPOSARCOMA


187/285

L#%o!sts +#th#n m$3o#' stromStrom hs r#ch c%#!!r$ net+or).

ROUND CELL

LIPOSARCOMA


188/285

More ((ress#"e form of m$3o#'!#%osrcom h"#n( !ess '#fferent#te'

roun' ce!!s.

PLEOMORPHIC LIPOSARCOMA


189/285

E3treme ce!!u!r %!eomor%h#smG#nt ce!!s.

TREATMENT


190/285

R'#c! e3c#s#on.50%recurrence rte.

Pro(nos#s of %!eomor%h#c !#%osrcom #s

much +orse s com%re' to m$3o#' &+e!! '#fferent#te'.

Pro(nos#s of or! !#%osrcom #s (oo'

Le#om$om


191/285

Rh'om$om

Musc!e

t#ssue

LEIOMYOMA


192/285

Benign tumor of smooth muscle within theoral cavity, usually of the blood vessels,

that appear as firm,movable,submucosal

nodule.

Most common s#tes re* uterus5 GIT &

s)#n.

Or! !e#om$om re rre.

ORAL LEIOMYOMA


193/285

S!o+ (ro+#n(

F#rm mucos! no'u!e

Cn occur t n$ (e

As$m%tomt#c most!$

L#%s5 ton(ue5 %!te & chee)s

HISTOPATHOLOGY


194/285

SOLID•9e!! c#rcumscr#e'•Inter!c#n( un'!es

of s%#n'!e sh%esmooth musc!e

ce!!s•M#tot#c f#(ures not

common

VASCULAR•9e!! c#rcumscr#e'•Mu!t#%!e tortuous

!oo' "esse!s +#thth#c)ene' +!!s

+#th #ntert+#n#n(un'!es of smooth

musc!e

EPIT7ELIOD•Com%ose'

%r#mr#!$ of

e%#the!o#' ce!!s

HISTOPATHOLOGY


195/285

Smooth musc!e ce!!s re s%#n'!e sh%e'+#th e!on(te' nuc!e# n' !unt en's

‘c#(r1sh%e'= %%ernce


196/285


197/285

TREATMENT


198/285

Loc! sur(#c! e3c#s#on.

LEIOMYOSARCOMA


199/285

Malignant neoplasm of smooth muscle

differentiation.

Most common s#tes* uter#ne +!! & GIT.

Or! !e#om$osrcom re rre

ORAL

LEIOMYOSARCOMA


200/285

M#''!e (e & o!'er 'u!ts

50%occur #n 6+ ones

En!r(#n( mss $ or m$ snot e %#nfu!

HISTOPATHOLOGY


201/285

Fsc#c!es of s%#n'!e sh%e' ce!!s.

P!eomor%h#sm & t$%#c! m#tot#c f#(ures

seen.

E%#the!o#' ce!!s !so %resent.

LEIOMYOSARCOMA


202/285

LEIOMYOSARCOMA


203/285

IMMUNOMARKERS


204/285

Desm#n

Smooth musc!e ct#n

Smooth musc!e m$os#nMusc!e s%ec#f#c ct#n

TREATMENT&

PROGNOSIS


205/285

R'#c! sur(#c! e3c#s#on.

Pro(nos#s for or! tumor #s not (oo' +#ththe %otent#! for !oc! recurrence &

'#stnt metsts#s.

RHABDOMYOMA


206/285

Benign neoplasm of skeletal muscle

Extremely rare.

Rhabdomyomas of head & neck areclassified into

A'u!t Fet!

ADULT

RHABDOMYOMA


207/285

CLINICAL FEATURES

M#''!e (e & o!'er'u!ts

Cn emu!t#no'u!r

& mu!t#centr#c

No'u!e ormss5 r%#'

(ro+th

70%foun'#n men

ADULT

RHABDOMYOMA


208/285

S#te

Or!c"#t$

F!oor ofthe mouth

Soft%!te

Bse ofton(ue

Phr$n3 Lr$n3

ADULT

RHABDOMYOMA


209/285

7ISTOPAT7OLOG8:9e!! c#rcumscr#e' tumor .

Com%ose' of !r(e %o!$(on! ce!!s h"#n(

un'nt (rnu!r eos#no%h#!#c

c$to%!sm.

Ce!!s sho+ %er#%her! "cuo!#,t#on +h#ch

(#"es s%#'er +e %%ernce.

Foc! ce!!s +#th cross str#t#ons re seen.


210/285

ADULT

RHABDOMYOMA


211/285

IMMUNO7ISTOC7EMICAL STUDIES:

Desm#n

M$o(!o#nMusc!e1s%ec#f#c ct#n.

FETAL

RHABDOMYOMA


212/285

CLINICAL FEATURES

8oun( ch#!'ren

Fce Per#ur#cu!rre(#on

M!es


213/285


214/285

TREATMENT


215/285


RHABDOMYOSARCOM

A


216/285

Malignant neoplasm characterized by

skeletal muscle differentiation.

RHABDOMYOSARCOM

A


217/285

RHABDOMYOSARCOM

A


218/285

RHABDOMYOSARCOM

A


219/285

RHABDOMYOSARCOM

A


220/285

RHABDOMYOSARCOM

A


221/285

HISTOPATHOLOGY


222/285

EMBR8ONAL R7ABDOM8OSARCOMA

Sm!! roun' or o"! ce!!s +#th h$%erchromt#c

nuc!e# & #n'#st#nct c$to%!sm.

Str% sh%e' rh'om$o!sts re seen.

Mr)ers:

Desm#n

M$o(en#n

Musc!e s%ec#f#c1ct#n


223/285

HISTOPATHOLOGY

ALVEOLAR R7ABDOM8OSARCOMA


224/285

A((re(tes of %oor!$ '#fferent#te' roun' to o"! ce!!s se%rte'

$ f#rous se%t.

Ce!!s 'emonstrte centr! !oss of cohes#"eness +h#ch resu!ts #n

!"eo!r %ttern.

Per#%her! ce!!s 'here to se%t! +!!s #n s#n(!e !$er n'

centr! ce!!s %%er to f!ot free!$ +#th#n the !"eo!r s%ce.

M#tos#s

Mu!t#nuc!ete' (#nt ce!!s.


225/285


226/285

PLEOMORPHIC

RHABDOMYOSARCOMA


227/285

TREATMENT


228/285


Chemother%$.

ANGIOSARCOMA


229/285

Rre m!#(nnc$ of "scu!r en'othe!#um+h#ch cn r#se from e#ther !oo' or

!$m%ht#c chnne!s.

More thn />? cses occur #n he' &

nec) re(#on.

Sc!% & forehe' re the most common

s#tes.

Or! !es#ons re rre.

APPEARANCE


230/285

ORALANGIOSARCOMA


231/285

HISTOPATHOLOGY


232/285

Inf#!trt#"e %ro!#fert#on of en'othe!#um !#ne'!oo' "esse!s.

Vesse!s form n nstomos#n( net+or)

En'othe!#! ce!!s re h$%erchromt#c &

t$%#c! n' ten' to %#!e +#th#n the

"scu!r Lum#n.

Increse m#tot#c ct#"#t$ seen.


233/285


234/285

IMMUNOHISTOCHEMICAL

STUDIES


235/285

CD-

Fctor VIII1re!te' nt#(en

TREATMENT&PROGNOSIS


236/285

R'#c! sur(#c! e3c#s#onR'#other%$

Pro(nos#s for fce & sc!% #s %oor .

Or! outcome #s etter

NASOPHARYNGEAL

ANGIOFIBROMA


237/285

Rre "scu!r & f#rous tumor !#)e !es#on

tht occurs on!$ #n nso%hr$n3.

Ben#(n !es#on ut !oc!!$ ((ress#"e &'estruct#"e eh"#our .

M$ re%resent "scu!r m!formt#on

then true neo%!sm.

NASOPHARYNGEAL

ANGIOFIBROMA


238/285

NASOPHARYNGEAL

ANGIOFIBROMA


239/285


240/285

NASOPHARYNGEAL

ANGIOFIBROMA


241/285


242/285

NASOPHARYNGEAL

ANGIOFIBROMA


243/285

TREATMENT

Sur(#c! e3c#s#on

R'#t#on ther%$ #n cse of recurrenceRecurrence #s >10>?

M!#(nnt trnsformt#on #nto

F#rosrcom.

LYMPHANGIOMA


244/285

Benign proliferation of lymphatic vessels

that occur as focal,superficial lesion

within the oral cavity and as a massive

diffuse lesion of neck cystic hygroma!.

LYMPHANGIOMA


245/285

These re 'e"e!o%ment! m!formt#ons of

!$m%ht#c t#ssue +h#ch 'o not

commun#cte +#th rest of the !$m%ht#c

s$stem.

LYMPHANGIOMA


246/285

LYMPHANGIOMA


247/285

CERVICALLYMPHANGIOMA


248/285


249/285


250/285

ORAL LYMPHANGIOMA


251/285


252/285

HISTOPATHOLOGY

Com%ose' of !$m%ht#c "esse!s sho+#n(


253/285

mr)e' '#!tt#on or c$st !#)e s%ces.


254/285

HISTOPATHOLOGY

Vesse!s #nf#!trte the soft t#ssues & m$


255/285

'emonstrte !$m%ho#' ((re(tes #n

the#r +!!s

HISTOPATHOLOGY

L#n#n( #s th#n & s%ce cont#ns


256/285

%rote#nceous f!u#' & some

!$m%hoc$tes.

.

HISTOPATHOLOGY

Intr or! tumors re !octe' 6ust eneth


257/285

the e%#the!#! surfce & often re%!ce

connect#"e t#ssue.

TREATMENT



258/285

7#(h recurrence rte #n cse of or!

!$m%hn(#oms.

Lo+ recurrence rte #n cse of cer"#c!

!$m%hn(#om.

Pro(nos#s #s (oo'.

Res%#rtor$ com%!#ct#ons & 'eth cn

occur .

HEMANGIOMA & VASCULAR

MALFORMATIONS

7EMANGIOMA


259/285

Ben#(n tumors of #nfnc$ tht sho+ r%#'

(ro+th %hse +#th en'othe!#! ce!!

%ro!#fert#on fo!!o+e' $ (r'u! #n"o!ut#on.

VASCULAR MALFORMATIONSStructur! nom!#es of !oo' "esse!s +#thout

en'othe!#! %ro!#fert#on. The$ re %resent

t #rth & %ers#st throu(hout !#fe.

HEMANGIOMA OFINFANCY


260/285


261/285

HEMANGIOMA OFINFANCY


262/285

HISTOPATHOLOGY

Numerous %!um% en'othe!#! ce!!s &

# '# t# t ! ! # )


263/285

#n'#st#nct "scu!r !um#n )no+n s

6u"en#!e or ce!!u!r hemn(#om.

As the !es#on mtures en'othe!#! ce!!s

f!tten n' "scu!r s%ces ecomemore e"#'ent.

In"o!ut#on* "scu!r s%ces !ess %rom#nent

n' re%!ce' $ f#rous connect#"et#ssue.


264/285


265/285

VASCULARMALFORMATIONS

PORT 9INE STAIN:

f f &


266/285

A "scu!r nom!$ of su%erf#c#! & 'ee%

'#!te' c%#!!r#es #n the s)#n %ro'uc#n(

re''#sh to %ur%!#sh '#sco!ort#on of s)#n.

Most common on the fce !on( the'#str#ut#on of tr#(em#n! ner"e.

0.3-1%#n ne+orns.

Pers#st throu(h out !#fe.


267/285

VASCULARMALFORMATIONS


268/285


269/285


270/285

HISTOPATHOLOGY

Do not sho+ ct#"e en'othe!#!

%ro!#fert#on


271/285

%ro!#fert#on.

C%#!!r$ m!formt#ons* c%#!!r$ s#,e'

"esse!s

Venous m!formt#ons* more '#!te'"esse!s

Arter#o1"enous m!formt#ons* m#3ture of

th#c) +!!e' rter#es5 "e#ns n'c%#!!r#es.


272/285


273/285

NEUROFIBROMA

It # f h !! ' # !


274/285

It r#ses from sch+nn ce!!s n' %er#neur!

f#ro!sts.

S#te* most common s#te #s s)#n. In or!

c"#t$5 ton(ue & ucc! mucos.

NEUROFIBROMATOSIS


275/285


276/285

DIAGNOSTIC CRITERIA FORNEUROFIBROMATOSIS TYPE I


277/285


278/285

DIAGNOSTIC CRITERIA FORNEUROFIBROMATOSIS TYPE I


279/285


280/285

ORALMANIFESTATIONS


281/285

ORALMANIFESTATIONS


282/285


283/285

COMPLICATIONS


284/285

PROGNOSIS

Pro(nos#s #n cse of M!#(nnt Per#%her!


285/285

Pro(nos#s #n cse of M!#(nnt Per#%her!

ner"e sheth tumor #s %oor +#th / $er

sur"#"! rte #n on!$ -/ cses.

A"er(e !#fes%n of NF- %t#ent #s re'uce'$ -/ $ers

Documents

Connective Tissue Lesions